Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
University of Amsterdam · Academic Medical Center · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
588
total citations
- FWCI
- 54.68
- Percentile
- 100%
- References
- 42
Citations per year
Authors
23- DBDominique Baeten
University of Amsterdam, Academic Medical Center
- XBXenofon Baraliakos
Rheumazentrum Ruhrgebiet
- JBJürgen Braun
Rheumazentrum Ruhrgebiet
- JSJoachim Sieper
Charité - Universitätsmedizin Berlin
- PEPaul Emery
Leeds Teaching Hospitals NHS Trust, NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds
Topics & keywords
Topics
Keywords
- Secukinumab
- Medicine
- Ankylosing spondylitis
- Placebo
- Clinical endpoint
- Internal medicine
- Adverse effect
- Clinical trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.